Harrow, Inc. (HROW)

NGM – Real Time Price. Currency in USD

42.07

+0.57 (1.37%)

At close: Jun 26, 2026, 4:00 PM EDT

42.00

-0.07 (-0.18%)

After-hours: Jun 26, 2026, 5:49 PM EDT

11.06.2026

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US

Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.

11.06.2026

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic eye condition that primarily affects children.

10.06.2026

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children.

27.05.2026

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair's 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.

13.05.2026

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.

12.05.2026

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript

12.05.2026

Harrow Q1 Earnings Call Highlights

Harrow NASDAQ: HROW executives said the company's first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized that underlying demand for its core ophthalmic products is accelerating.

Videos

No Data

There is no data to display

Press releases

10.06.2026

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

13.05.2026

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

11.05.2026

Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to deliver 2026 revenue of over $100 million Quarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 million IHEEZO® unit demand increased 18% year-over-year, with 82% of units from retina accounts TRIESENCE® unit demand more than doubled year-over-year, the sixth consecutive quarter of growth Second Quarter revenue expected between $71 million and $81 million Full-year 2026 revenue guidance reaffirmed at $350 million to $365 million Cash and cash equivalents of $94.6 million as of March 31, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

16.04.2026

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclonidine hydrochloride ophthalmic solution) has been assigned a permanent J-Code (J2374) by the Centers for Medicare & Medicaid Services (CMS).

Harrow, Inc. (HROW)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Harrow, Inc. (HROW)

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript

Harrow Q1 Earnings Call Highlights

Videos

No Data

Press releases

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Harrow Announces First Quarter 2026 Financial Results

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript

Harrow Q1 Earnings Call Highlights

Videos

No Data

Press releases

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Harrow Announces First Quarter 2026 Financial Results

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

Search stocks

Harrow, Inc. (HROW)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Harrow, Inc. (HROW)

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript

Harrow Q1 Earnings Call Highlights

Videos

No Data

Press releases

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Harrow Announces First Quarter 2026 Financial Results

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript

Harrow Q1 Earnings Call Highlights

Videos

No Data

Press releases

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Harrow Announces First Quarter 2026 Financial Results

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%